Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Novacyt

Market Cap 28.26M 32.17M 26.04M 24.38M 45.67M 3.05B 46.44M 313M 121M 1.5B 121M 118M 5.2B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 30.22M 34.39M 27.84M 26.06M 48.83M 3.26B 49.66M 334M 129M 1.6B 129M 126M 5.56B EV / Sales 2026 *
0.99x
EV / Sales 2027 * 0.95x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-5.90%
6 months-5.90%
Current year-5.90%
Current year 0.48
Extreme 0.48
0.48
1 year 0.48
Extreme 0.48
0.55
3 years 0.48
Extreme 0.48
1.25
5 years 0.48
Extreme 0.48
5.77
10 years 0
Extreme 0
16
Manager TitleAgeSince
Chief Executive Officer 53 2024-04-30
Director of Finance/CFO 44 2019-12-31
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Director/Board Member 75 2006-07-02
Director/Board Member 60 2017-06-26
Director/Board Member 44 2024-01-01
Change 5-day change 1-year change 3-year change Capi.($)
-5.90%-.--% - - 32.01M
+1.63%+0.81%-37.21%-42.17% 547M
-7.63%-27.12%+158.93% - 412M
-5.59%+8.81%+56.59%+103.16% 133M
-3.39%-9.14%-35.71%+11.47% 131M
Average -4.18%-7.90%+35.65%+24.16% 305.66M
Weighted average by Cap. -2.89%-9.91%+39.24%-9.59%

Financials

2026 *2027 *
Net sales 30.52M 34.75M 28.13M 26.33M 49.33M 3.29B 50.16M 338M 131M 1.61B 130M 128M 5.61B 34.86M 39.68M 32.12M 30.07M 56.34M 3.76B 57.29M 386M 149M 1.84B 149M 146M 6.41B
Net income - -
Net Debt 1.96M 2.23M 1.8M 1.69M 3.16M 211M 3.21M 21.64M 8.38M 103M 8.36M 8.18M 360M 4.84M 5.51M 4.46M 4.18M 7.83M 522M 7.96M 53.57M 20.74M 256M 20.69M 20.25M 890M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216

Annual profits - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!